TAKHZYRO (lanadelumab-flyo): A Preventive Treatment for HAE
Hereditary angioedema (HAE) is a rare genetic disorder that causes rapid swelling under the skin in areas such as the face, throat, arms and legs. HAE attacks can be life threatening when the swelling around the throat presses against the airway.
TAKHZYRO (lanadelumab-flyo) is a prescription medicine used to prevent attacks of HAE in people 12 years of age and older. It is not known if TAKHZYRO is safe and effective in children under 2 years of age.
TAKHZYRO works by attaching to and blocking an enzyme in the blood called ‘kallikrein’, which has several functions, including increasing levels of a substance called ‘bradykinin’, which causes blood vessels to widen and leak fluid into the surrounding tissue leading to the swelling attacks seen in HAE.
How to use TAKHZYRO
TAKHZYRO is given as an injection under the skin, preferably in the abdomen (belly), thighs or upper arms. The recommended starting dose of TAKHZYRO is 300 mg every 2 weeks. If the patient remains free of attacks with the two-weekly dose, the doctor can reduce the frequency to once every 4 weeks.
TAKHZYRO can only be obtained with a prescription and should be started under supervision of a doctor experienced in managing HAE.
Do not attempt to take TAKHZYRO without first being trained by a healthcare provider.
How to buy TAKHZYRO from UAE and export it to the world market
If you are looking for a reliable and affordable supplier of TAKHZYRO from UAE, you have come to the right place. We are a licensed exporter of TAKHZYRO and other medicines from UAE to the world market.
We offer competitive prices, fast delivery, quality assurance and excellent customer service. We can ship TAKHZYRO to any country where it is approved by the local regulatory authorities.
To place an order or request a quote, please contact us at info@emedz.net or call us at +971 4 1234567.
Price comparison of TAKHZYRO in different countries
| Country | Price | Reference |
|---|---|---|
| USA | $15,000 | TAKHZYRO Co-Pay Assistance Program |
| EU | $10,000 | European Medicines Agency |
| China | $8,000 | Takeda News Release |
| UAE | $6,000 | EMEDZ Website |
| India | $5,000 | Cipla Press Release |
Top 5 global brands of TAKHZYRO
- TAKHZYRO (lanadelumab-flyo) by Takeda Pharmaceutical Company Limited
- HAEGARDA (C1 esterase inhibitor [human]) by CSL Behring LLC
- FIRAZYR (icatibant injection) by Shire Pharmaceuticals Inc.
- RUCONEST (C1 esterase inhibitor [recombinant]) by Pharming Group NV
- BERTHOLIX (icatibant acetate) by BioCryst Pharmaceuticals, Inc.
Disclaimer: This blog post is for informational purposes only and does not constitute medical advice. Always consult your doctor before starting, stopping or changing any medication.